Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) EBITDA: 2017-2020

Historic EBITDA for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to -$11.3 million.

  • Cogent Biosciences' EBITDA fell 593.60% to -$11.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$74.8 million, marking a year-over-year decrease of 135.09%. This contributed to the annual value of -$74.8 million for FY2020, which is 135.09% down from last year.
  • Per Cogent Biosciences' latest filing, its EBITDA stood at -$11.3 million for Q4 2020, which was up 77.32% from -$50.0 million recorded in Q3 2020.
  • In the past 5 years, Cogent Biosciences' EBITDA ranged from a high of $2.3 million in Q4 2019 and a low of -$50.0 million during Q3 2020.
  • Over the past 3 years, Cogent Biosciences' median EBITDA value was -$9.6 million (recorded in 2018), while the average stood at -$11.8 million.
  • As far as peak fluctuations go, Cogent Biosciences' EBITDA soared by 126.73% in 2019, and later crashed by 593.60% in 2020.
  • Quarterly analysis of 4 years shows Cogent Biosciences' EBITDA stood at -$6.7 million in 2017, then declined by 28.61% to -$8.6 million in 2018, then spiked by 126.73% to $2.3 million in 2019, then crashed by 593.60% to -$11.3 million in 2020.
  • Its EBITDA stands at -$11.3 million for Q4 2020, versus -$50.0 million for Q3 2020 and -$7.4 million for Q2 2020.